RNU6-1187P: A Potential Drug Target and Biomarker for Small Nuclear RNA-Containing Glioblastoma

Target Name: RNU6-1187P

NCBI ID: G106481554

RNU6-1187P

Other Name(s): RNA, U6 small nuclear 1187, pseudogene

RNU6-1187P: A Potential Drug Target and Biomarker for Small Nuclear RNA-Containing Glioblastoma

Glioblastoma is one of the most aggressive forms of cancer, with a poor prognosis due to the high recurrence rates and resistance to conventional therapies. Despite advancements in cancer treatment, the mortality rate for glioblastoma remains high, and there is a significant need for new and effective therapies to improve outcomes.

Small nuclear RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in regulating gene expression and has been implicated in various cellular processes, including cell growth, apoptosis, and immune responses. High levels of snRNA have been observed in various types of cancer, including glioblastoma.

RNA, U6 small nuclear 1187 (RNA-1187) is a pseudogene that has been identified in various tissues, including brain, and is considered as a potential biomarker for various diseases, including cancer. RNA-1187 has been shown to be expressed in various types of cancer, including glioblastoma, and has been associated with poor prognosis in patients with these diseases.

RNA-1187 is a small molecule that can interact with various cellular components, including proteins and RNA molecules. Its unique structure and function make it an attractive drug target for small molecules, including anti-cancer drugs.

Drugs that target RNA-1187 have the potential to inhibit its activity and reduce the growth of cancer cells. This strategy has been used in the development of various anti-cancer drugs, including small molecule inhibitors and RNA-based therapeutics.

RNA-1187 has also been shown to play a role in the regulation of cellular processes that are important for cancer progression, including cell cycle progression, apoptosis, and angiogenesis. Its role in these processes makes it an attractive target for drugs that aim to disrupt these processes and inhibit cancer cell growth.

Targeting RNA-1187

Several small molecules have been shown to target RNA-1187 and have been investigated as potential anti-cancer drugs. One of the most promising targets is the small molecule inhibitor, RNA-1187 inhibitor, which has been shown to inhibit the activity of RNA-1187 and reduce the growth of cancer cells.

The small molecule inhibitor, RNA-1187 inhibitor, is a compound that can interact with RNA-1187 and prevent it from interacting with cellular components, including proteins and RNA molecules. This strategy has been used to develop RNA-1187 inhibitors that can be used in the treatment of various types of cancer, including glioblastoma.

Another approach to targeting RNA-1187 is the use of RNA-based therapeutics, which use RNA molecules to deliver targeting agents directly to cancer cells. One of the most promising RNA-based therapeutics is the small molecule RNA-1187 nanoparticles, which have been shown to be effective in delivering RNA-1187 inhibitors to cancer cells.

RNA-1187 is also a potential biomarker for various types of cancer, including glioblastoma. Its presence and levels can be used as a diagnostic marker for cancer and as a target for targeted therapies.

Conclusion

RNA-1187 is a pseudogene that has been identified in various tissues, including brain, and is considered as a potential biomarker for various diseases, including cancer. Its unique structure and function make it an attractive drug target for small molecules, including anti-cancer drugs.

The small molecule inhibitor, RNA-1187 inhibitor, is a compound that can interact with RNA-1187 and prevent it from interacting with cellular components, including proteins and RNA molecules. RNA-

Protein Name: RNA, U6 Small Nuclear 1187, Pseudogene

The "RNU6-1187P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6-1187P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets